Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Consensus molecular subtypes classification of colorectal cancer as a predictive factor for chemotherapeutic efficacy against metastatic colorectal cancer

ABSTRACT: Consensus molecular subtypes classification of colorectal cancer as a predictive factor for chemotherapeutic efficacy against metastatic colorectal cancer

PROVIDER: PRJNA413394 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

A consensus molecular subtypes classification strategy for clinical colorectal cancer tissues

Project description:This work presents a novel Consensus Molecular Subtypes (CMS) classifier for colorectal cancer (CRC), optimized for degraded RNA stemming from clinical formalin-fixed paraffin-embedded tissue samples.

2024-05-22 | GSE267010 | GEO

A consensus molecular subtypes classification strategy for clinical colorectal cancer tissues

Project description:A consensus molecular subtypes classification strategy for clinical colorectal cancer tissues

| PRJNA1109343 | ENA

Consensus molecular subtypes classification of colorectal cancer as a predictive factor for chemotherapeutic efficacy against metastatic colorectal cancer

Project description:Gene expression profile from 193 formalin-fixed and paraffin embedded primary tumor samples.

2018-05-08 | GSE104645 | GEO

Consensus molecular subtype transition during progression of colorectal cancer

Project description:Consensus molecular subtype transition during progression of colorectal cancer

| PRJNA994462 | ENA

Matrisome-focused integrative omics analysis reveals stromal phenotypes associated with consensus molecular subtypes in colorectal cancer

Project description:Matrisome-focused integrative omics analysis reveals stromal phenotypes associated with consensus molecular subtypes in colorectal cancer This reseaerch is conducted using colorectal cancer. TMT 11plex experiment

2022-10-27 | MSV000090604 | MassIVE

Consensus molecular subtypes classification of colorectal cancer as a predictive factor for chemotherapeutic efficacy against metastatic colorectal cancer.

Project description:The consensus molecular subtypes (CMS) classification is one of the most robust colorectal cancer (CRC) classifications based on comprehensive gene expression profiles. This study aimed to clarify whether the CMS is a predictive factor for therapeutic effects of standard chemotherapies for metastatic CRC (mCRC). We retrospectively enrolled 193 patients with mCRCs, and using comprehensive gene expression data, classified them into 4 subtypes: CMS1-CMS4. The associations between the subtypes and treatment outcomes were analyzed. Regarding first-line chemotherapy, irinotecan (IRI)-based chemotherapy was significantly superior to oxaliplatin (OX)-based chemotherapy for progression-free survival (PFS; hazard ratio [HR] = 0.31, 95% confidence interval [CI] 0.13-0.64) and overall survival (OS; HR = 0.45, 95% CI 0.19-0.99) in CMS4. Regarding the anti-epidermal growth factor receptor (anti-EGFR) therapy, CMS1 showed particularly worse PFS (HR = 2.50, 95% CI 1.31-4.39) and OS (HR = 4.23, 95% CI 1.83-9.04), and CMS2 showed particularly good PFS (HR = 0.67, 95% CI 0.44-1.01) and OS (HR = 0.49, 95% CI 0.27-0.87) compared with the other subtypes. The biological characteristics of CMS may influence the efficacy of chemotherapy. CMS might be a new predictive factor for the efficacy of chemotherapy against mCRCs.

| S-EPMC5922348 | biostudies-literature

Colorectal Adenomas and Consensus Molecular Subtyping

Project description:Colorectal Adenomas and Consensus Molecular Subtyping

| PRJNA423096 | ENA

Mutational classification of colorectal cancer

Project description:Mutational classification of colorectal cancer

| PRJNA319429 | ENA

Consensus Molecular Subtype predicts differential vulnerability of colorectal cancer to the survivin suppressant YM155 I

Project description:Tumor heterogeneity is a major challenge to the treatment of colorectal cancer (CRC). Recently, a transcriptome-based classification was developed, segregating CRC into four consensus molecular subtypes (CMS) with distinct biological and clinical characteristics. Here, we applied the CMS classification on CRC cell lines to identify novel subtype-specific drug vulnerabilities. We combined publicly available transcriptome data from multiple resources to assign 159 CRC cell lines to CMS. By integrating results from large scale drug screens, we discovered that CMS1 cancer is highly vulnerable to the survivin suppressor YM155. We confirmed our results using an independent panel of CRC cell lines and demonstrate a 100-fold higher sensitivity of CMS1 lines. This vulnerability was specific to YM155 and not observed for commonly used chemotherapeutic agents. In CMS1 cancer, low concentrations of YM155 induced apoptosis and expression signatures associated with NFkappaB and ER stress mediated apoptosis signaling. Using a genome-wide CRISPR/Cas9 screen, we discovered a novel role of genes involved in LDL-receptor recycling as modulators of YM155 response in CMS1 CRC. Our work shows that combining drug response data with CMS classification in cell lines can reveal specific vulnerabilities and propose YM155 as novel CMS1 specific drug.

2018-07-03 | GSE116529 | GEO

Consensus molecular subtype transition during progression of colorectal cancer [NanoClassifier Gene Set]

Project description:Consensus molecular subtype transition during progression of colorectal cancer [NanoClassifier Gene Set]

| PRJNA994465 | ENA